<p>Chemomab Therapeutics Ltd. announced the publication of results from its Phase 2 SPRING trial evaluating nebokitug in patients with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. The study found that nebokitug, an anti-CCL24 monoclonal antibody, was safe and well tolerated compared to placebo at 15 weeks, with no safety signals observed for up to 48 weeks of treatment. The results indicated dose-dependent biological activity, particularly in patients with moderate to advanced fibrosis. Chemomab Therapeutics plans to advance nebokitug into a Phase 3 registration trial. The results from the SPRING trial have already been published and presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595148-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CMMB

<p>Chemomab Therapeutics announced positive Phase 2 results for nebokitug in primary sclerosing cholangitis, showing safety and dose-dependent biological activity. The drug was well tolerated with no safety signals up to 48 weeks. The company plans to advance to a Phase 3 trial. Results were published in the American Journal of Gastroenterology.</p>

Chemomab Therapeutics Publishes Positive Phase 2 Results for Nebokitug in Primary Sclerosing Cholangitis